Queensland Residents in Australia Embrace Digital Driver Licences Powered and Protected by Thales
11.6.2024 10:00:00 EEST | Business Wire | Press release
The Queensland Digital Licence App has reached over 500,000 users since its launch on 1 November, 2023, showing a clear appetite from Queensland residents for safe and secure digital identity. Thales and Queensland Department of Transport and Main Roads (TMR) released the new app to all Queensland residents following a successful pilot and an extended trial in Townsville, where engagement with real end users, businesses, and industry groups provided valuable insights to the project in readiness for the launch.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611475244/en/
Credit: Queensland Department of Transport and Main Roads
With core technology provided by Thales, supported by development and operations from local partners Code Heroes and Aliva, the QLD Digital Licence app is simple to use, secure, and designed with data security and user privacy in mind. The app includes features such as multi-factor authentication, integration with the Queensland Digital Identity (QDI) service, and built-in verification for secure user-to-user information exchange. The app's consent-based design gives the individual control over their identity data – users can present or share information from the app by selecting from common use cases that disclose only the relevant information for the transaction, such as ‘proof of age’, which displays an ‘over 18’ screen without exposing date of birth, address, or driving information – a popular feature. The app currently provides digital driver licences, proof of age (18+) cards, and marine licences, with the potential for more digital documents in future.
Businesses that need to check identity or age requirements to provide goods or services can download the standalone (QLD) Verifier for Digital Licence app, which electronically confirms the authenticity of data received from a Digital Licence app. Digital verification is also expected to help businesses reduce the need to store sensitive identity data attributes as the process of verification is quick and simple, allowing for point-in-time verification in a wide range of use cases. The requirements to develop verification functionality are publicly available within the mobile driving licence app standard (ISO/IEC18013-5), allowing the larger ecosystem to build complementary verification solutions and enhance the usability of the digital licence in everyday life.
The QLD Digital Licence app and Verifier for Digital Licence app developed by Thales, are available now to Queensland residents via the mobile app stores.
“Nothing is more important that your private data, which should be highly protected. We are proud of the current success of the Queensland Digital Licence app, ensuring the safety and security of private information while offering a modern digital experience. The app undergoes rigorous privacy and information security testing to protect identity. It aligns with international standards for mobile driver licences, setting the standard for mobile driver licence apps across Australia and the world” commentedMark Bailey, Minister for Transport and Main Roads.
“Through this collaboration, Thales demonstrates a field-proven capacity to provide citizens with highly convenient and secure solutions, allowing them to reap the full benefits of digitalization. The Queensland Digital Licence App is a significant milestone in the digital ID market, showing the growing importance of and appetite for alignment to international standards for mobile driving licences and interoperability across country borders” said Youzec Kurp, Senior Vice President Identity and Biometric Solutions at Thales.
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.
It develops products and solutions that help make the world safer, greener and more inclusive.
The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.
Thales has close to 81,000 employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.
PLEASE VISIT
Thales Group
Digital Identity & Security
Thales
Thales Digital Identity and Security
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240611475244/en/
Contact information
PRESS CONTACT
Thales, Media Relations
Digital Identity and Security
Vanessa Viala
+33 (0)6 07 34 00 34
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom